Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR Japan: Long-acting intramuscular vs subcutaneous cabotegravir + rilpivirine maintenance in HIV-1
jRCT2080223432Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1, sponsored by GSK. Started Jan 2017; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080223432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223432.